Cargando…
The quality of antiretroviral medicines: an uncertain problem
OBJECTIVES: Substandard and falsified (SF) antiretrovirals (ARVs) risk poor outcomes and drug resistance, potentially affecting millions of people in need of treatment and prevention. We assessed the available evidence on SF ARV and related medical devices to discuss their potential public health im...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030546/ https://www.ncbi.nlm.nih.gov/pubmed/36921990 http://dx.doi.org/10.1136/bmjgh-2022-011423 |
_version_ | 1784910400135888896 |
---|---|
author | Do, Ngan Thi Boupha, Phonepasith Newton, Paul N Caillet, Céline |
author_facet | Do, Ngan Thi Boupha, Phonepasith Newton, Paul N Caillet, Céline |
author_sort | Do, Ngan Thi |
collection | PubMed |
description | OBJECTIVES: Substandard and falsified (SF) antiretrovirals (ARVs) risk poor outcomes and drug resistance, potentially affecting millions of people in need of treatment and prevention. We assessed the available evidence on SF ARV and related medical devices to discuss their potential public health impact. METHODS: Searches were conducted in Embase, PubMed, Google, Google Scholar, Web of Science and websites with interest in ARV quality in English and French up to 30 November 2021. Publications reporting on the prevalence of SF ARV were assessed in a quantitative analysis using the Medicine Quality Assessment Reporting Guidelines (MEDQUARG). RESULTS: We included 205 publications on SF ARV and 11 on SF medical devices. Nineteen prevalence surveys of SF ARV, published between 2003 and 2021, were included, with no surveys relevant to SF medical devices. The prevalence survey sample size ranged from 3 to 2630 samples (median (Q1–Q3): 16.0 (10.5–44.5); 3 (15.8%) used random outlet sampling methods. Of the 3713 samples included in the prevalence surveys, 1.4% (n=51) failed at least one test. Efavirenz, nevirapine and lamivudine-nevirapine-stavudine combination were the most surveyed ARV with failure frequencies of 3.6% (7/193), 2.6% (5/192) and 2.8% (5/177), respectively. The median (Q1%–Q3%) concordance with the MEDQUARG criteria was 42.3% (34.6%–55.8%). CONCLUSION: These results suggest that there are few data in the public domain of the quality of ARV in supply chains; the proportion of SF ARV is relatively low in comparison to other classes of essential medicines. Even a low proportion of the ARV supply chain being poor quality could make a large difference in the HIV/AIDS international landscape. The 95-95-95 target for 2026 and other international targets could be greatly hampered if even 1% of the millions of people taking ARV (for both prevention and prophylaxis) receive medicines that do not meet quality standards. More surveillance of SF ARV is needed to ensure issues are detected. |
format | Online Article Text |
id | pubmed-10030546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-100305462023-03-23 The quality of antiretroviral medicines: an uncertain problem Do, Ngan Thi Boupha, Phonepasith Newton, Paul N Caillet, Céline BMJ Glob Health Original Research OBJECTIVES: Substandard and falsified (SF) antiretrovirals (ARVs) risk poor outcomes and drug resistance, potentially affecting millions of people in need of treatment and prevention. We assessed the available evidence on SF ARV and related medical devices to discuss their potential public health impact. METHODS: Searches were conducted in Embase, PubMed, Google, Google Scholar, Web of Science and websites with interest in ARV quality in English and French up to 30 November 2021. Publications reporting on the prevalence of SF ARV were assessed in a quantitative analysis using the Medicine Quality Assessment Reporting Guidelines (MEDQUARG). RESULTS: We included 205 publications on SF ARV and 11 on SF medical devices. Nineteen prevalence surveys of SF ARV, published between 2003 and 2021, were included, with no surveys relevant to SF medical devices. The prevalence survey sample size ranged from 3 to 2630 samples (median (Q1–Q3): 16.0 (10.5–44.5); 3 (15.8%) used random outlet sampling methods. Of the 3713 samples included in the prevalence surveys, 1.4% (n=51) failed at least one test. Efavirenz, nevirapine and lamivudine-nevirapine-stavudine combination were the most surveyed ARV with failure frequencies of 3.6% (7/193), 2.6% (5/192) and 2.8% (5/177), respectively. The median (Q1%–Q3%) concordance with the MEDQUARG criteria was 42.3% (34.6%–55.8%). CONCLUSION: These results suggest that there are few data in the public domain of the quality of ARV in supply chains; the proportion of SF ARV is relatively low in comparison to other classes of essential medicines. Even a low proportion of the ARV supply chain being poor quality could make a large difference in the HIV/AIDS international landscape. The 95-95-95 target for 2026 and other international targets could be greatly hampered if even 1% of the millions of people taking ARV (for both prevention and prophylaxis) receive medicines that do not meet quality standards. More surveillance of SF ARV is needed to ensure issues are detected. BMJ Publishing Group 2023-03-15 /pmc/articles/PMC10030546/ /pubmed/36921990 http://dx.doi.org/10.1136/bmjgh-2022-011423 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Do, Ngan Thi Boupha, Phonepasith Newton, Paul N Caillet, Céline The quality of antiretroviral medicines: an uncertain problem |
title | The quality of antiretroviral medicines: an uncertain problem |
title_full | The quality of antiretroviral medicines: an uncertain problem |
title_fullStr | The quality of antiretroviral medicines: an uncertain problem |
title_full_unstemmed | The quality of antiretroviral medicines: an uncertain problem |
title_short | The quality of antiretroviral medicines: an uncertain problem |
title_sort | quality of antiretroviral medicines: an uncertain problem |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030546/ https://www.ncbi.nlm.nih.gov/pubmed/36921990 http://dx.doi.org/10.1136/bmjgh-2022-011423 |
work_keys_str_mv | AT donganthi thequalityofantiretroviralmedicinesanuncertainproblem AT bouphaphonepasith thequalityofantiretroviralmedicinesanuncertainproblem AT newtonpauln thequalityofantiretroviralmedicinesanuncertainproblem AT cailletceline thequalityofantiretroviralmedicinesanuncertainproblem AT donganthi qualityofantiretroviralmedicinesanuncertainproblem AT bouphaphonepasith qualityofantiretroviralmedicinesanuncertainproblem AT newtonpauln qualityofantiretroviralmedicinesanuncertainproblem AT cailletceline qualityofantiretroviralmedicinesanuncertainproblem |